SIGN UP
LOG IN
I
IMRX
Immuneering Corp
1.28
-0.01-0.96%Opening12:56 05/02 EDT
OPEN/PREV CLOSE1.320/1.290
TODAY RANGE1.260-1.320
VOL77.54K
MARKET CAP45.98M
52 WEEK RANGE1.000-3.830
AVG VOL (3M)206.90K
% TURNOVER0.22%
TURNOVER--
P/E (TTM)-0.6276
% RANGE4.65%
EPS(TTM)-2.0358
P/E(FORWARD)-0.7178
P/B0.9585
BVPS1.333
DIVIDEND--
P/S4,050.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP34.92M
SHARES OUTSTANDING35.99M
NEXT EARNINGS--
FREE FLOAT27.33M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Press release·04/07 13:20
Based on the provided financial report articles, the title of the article is: "Immuneering Corporation (IMRX) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Dow Jones·03/24 11:53
Immuneering Is Maintained at Buy by Chardan Capital
Dow Jones·03/24 11:53
Immuneering Price Target Maintained With a $13.00/Share by Chardan Capital
Benzinga·03/24 11:43
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
TipRanks·03/22 03:51
Immuneering Corp. Reports Promising Cancer Trial Results
Dow Jones·03/21 20:30
Press Release: Immuneering Corporation Announces Grant of Inducement Award
TipRanks·03/21 19:50
Immuneering management to meet with Oppenheimer
Barchart·03/21 15:30
Immuneering Corporation Announces Grant of Inducement Award
Dow Jones·03/21 13:07
Immuneering Price Target Maintained With a $12.00/Share by Needham
Benzinga·03/21 12:57
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
TipRanks·03/21 10:45
Immuneering’s Strategic Advancements and Financial Strength Bolster Buy Rating
Press release·03/20 23:25
Based on the provided financial report articles, the title of the article is: "Immuneering Corporation (IMRX) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Seeking Alpha·03/20 20:40
Immuneering GAAP EPS of -$0.58
TipRanks·03/20 20:35
Immuneering reports Q4 EPS (58c), consensus (44c)
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.